NASDAQ: MOLNMolecular Partners Ag Stock
$4.33-0.06 (-1.37%)
Updated Mar 14, 2025
MOLN Price
$4.33
Fair Value Price
$0.95
Market Cap
$159.62M
52 Week Low
$3.32
52 Week High
$12.70
P/E
-2.45x
P/B
1.01x
P/S
28.54x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.52M
Earnings
-$60.05M
Gross Margin
100%
Operating Margin
-1,086.58%
Profit Margin
-1,087.4%
Debt to Equity
0.12
Operating Cash Flow
-$66M
Beta
0.62
Next Earnings
Apr 17, 2025
Ex-Dividend
N/A
Next Dividend
N/A
MOLN Overview
Molecular Partners AG discovers, develops, and commercializes therapeutic proteins. The company's pipeline includes Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of Neovascular Age-Related Macular Degeneration, as well as for Diabetic Macular edema, and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. It is also developing MP0423 for treating COVID-19, MP0533, a CD3 T cell candidate for Acute Myeloid Leukemia, and MP0250 for Vascular Endothelial Growth Factor and Hepatocyte Growth Factor. Molecular Partners was incorporated in 2004 and is headquartered in Schlieren, CH.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MOLN's potential to beat the market
- MOLN doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MOLN
RankedUnranked of 484
RankedUnranked of 484
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.84 | A | |
| $137.96 | A | |
| $8.16 | A |
Be the first to know about important MOLN news, forecast changes, insider trades & much more!
MOLN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MOLN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MOLN ($4.33) is overvalued by 357.33% relative to our estimate of its Fair Value price of $0.95 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MOLN ($4.33) is not significantly undervalued (357.33%) relative to our estimate of its Fair Value price of $0.95 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MOLN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MOLN due diligence checks available for Premium users.
Valuation
MOLN fair value
Fair Value of MOLN stock based on Discounted Cash Flow (DCF)
Price
$4.33
Fair Value
$0.95
Overvalued by
357.33%
MOLN ($4.33) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MOLN ($4.33) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MOLN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MOLN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.45x
Industry
-118.09x
Market
3,446.61x
MOLN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.01x
Industry
4.68x
MOLN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MOLN's financial health
Profit margin
Revenue
$0.0
Net Income
-$12.5M
Profit Margin
0%
MOLN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
MOLN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$176.1M
Liabilities
$18.8M
Debt to equity
0.12
MOLN's short-term assets ($171.42M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MOLN's short-term assets ($171.42M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MOLN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MOLN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$14.7M
Investing
-$5.0M
Financing
$17.0M
MOLN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MOLN vs Biotech Stocks
Molecular Partners Ag Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.